Muscle cramp
Drug research and approvals for muscle cramp: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 8 studies of muscle cramp are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 8
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg CrampsNCT07651514 · Not applicable · StudySetGo · starts Oct 10, 2026
- Sugammadex-Induced Clenching During Neuromuscular Blockade ReversalNCT06962007 · Not applicable · Wonkwang University Hospital · starts Jul 1, 2025
- Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After RadiotherapyNCT06734598 · Phase 4 · National Taiwan University Hospital · starts Dec 1, 2024
- The Application of Wide Pulse High Frequency Neuromuscular Electrical Stimulation in Disorders Associated With…NCT05908214 · Not applicable · University of Lausanne · starts Oct 1, 2023
- Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary DysmenorrheaNCT05640232 · Phase 3 · EMS · starts Jun 11, 2025
- Video-supervised Motor and Awareness Training in Writer's CrampNCT04611009 · Phase 2 · University Hospital Schleswig-Holstein · starts Jun 26, 2020
- Brain Networks in DystoniaNCT03042962 · Not reported · Massachusetts Eye and Ear Infirmary · starts Aug 1, 2015
- Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With CirrhosisNCT02423395 · Phase 3 · Sherief Abd-Elsalam · starts Jan 1, 2015
Approved 10
- LidocaineSodium channel alpha subunit blocker
- AcetaminophenCyclooxygenase inhibitor
- IbuprofenCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- QuinineFerriprotoporphyrin IX inhibitor
- MentholTransient receptor potential cation channel subfamily M member 8 opener
- CapsaicinVanilloid receptor opener
- AspirinCyclooxygenase inhibitor
- EpinephrineAdrenergic receptor agonist
- Methyl salicylate
Phase 3 5
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- NitroglycerinSoluble guanylate cyclase activator
- Botulinum toxin type aSynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
- NicardipineVoltage-gated L-type calcium channel blocker
- PregabalinVoltage-gated calcium channel modulator
Phase 2 6
- MisoprostolProstanoid EP3 receptor agonist
- NimodipineMineralocorticoid receptor antagonist
- MilrinonePhosphodiesterase 3A inhibitor
- Levocarnitine
- Papaverine
- Menaquinone 6
How its trials ended
89 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 33% met their primary endpoint, 0% missed it and 67% stopped early.
- Completed, result not reported4045%
- Status unknown1820%
- Ongoing1315%
- Met its primary endpoint67%
- Stopped: enrollment or feasibility44%
- Stopped: other or unclear44%
- Stopped: sponsor or business decision22%
- Stopped: lack of efficacy11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA